Koo

I dont mean to plagiarize - but this post from Tundup on 6/21/18 is relevant to this discussion:

" If BetonMace achieved 25%-30% RRR with NNT of 50 then it would result in attractive payor economics. The Incremental Cost Efficiency Ratio (ICER), which measures how much extra money you need to spend over 1 year to save one event,  would be very interesting. i.e. if a hospital admission costs >$200,000 per patient then an interesting ICER is <$200k. For the big SGLT2 trial which lasted 5 years and had NNTs of 70 that equals 350 patient years to save 1 event, so if cost of drug is $3000/year that results in a ICER of $1m just to save 1 event. It’s NOT economic.

Working back from $200,000 hospital admission cost then a RRR of 30% and NNT of 50 (over ONE year) would support a price of $4000-$5000. If NNT is as low as 30 then Apabetalone could be priced at $6000-$7000 per year.  "

I would suggest that you read the complete post from Tundup on 6/21/18

Looking Good!

Chicagoest